Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 332, Issue 1, pp 57–61 | Cite as

Differential effect of stimulation strength in mouse vas deferens on inhibition of neuroeffector transmission by receptor type selective opioids

  • D. Ramme
  • P. Illes


In the mouse isolated vas deferens the amplitude of excitatory junction potentials (e.j.p.s) recorded intracellularly from smooth muscle cells varied with the strength of stimulation. Receptor type selective opioids were tested in this preparation. The μ-agonist normorphine (2,000 nmol/l) reduced the amplitude of e.j.p.s and shifted the stimulus-response curve in a parallel way to the right. By contrast, the ϰ-agonist U-50488 (1,000 nmol/l) and the δ-agonist [d-Ala2,d-Leu5]-enkephalin (2 nmol/l) caused a nonparallel shift of the curve. In addition, opioids having a lower selectivity for one type of receptor were also used. The preferential ϰ-agonists ethylketocyclazocine (40 nmol/l) and dynorphin A1–13 (100 nmol/l) produced parallel and nonparallel shifts, respectively. Thus, normorphine and ethylketocyclazocine were more effective in depressing e.j.p.s evoked by low intensities of stimulation than those evoked by high intensities of stimulation. U-50488, dynorphin A1–13 and [d-Ala2,d-Leu5]-enkephalin caused an equal depression of e.j.p.s evoked by either intensity of stimulation. The preferential μ- and δ-antagonists naloxone (1,000 nmol/l) and ICI 154129 (10,000 nmol/l), reversed the action of the respective agonists normorphine and [d-Ala2,d-Leu5]-enkephalin. In addition, ICI 154129 (10,000 nmol/l) reversed the action of dynorphin A1–13, as well. The preferential ϰ-antagonist MR-2266 (1,000 nmol/l) prevented the effect of both ethylketocyclazocine and U-50488. It is concluded that under the conditions of these experiments normorphine and ethylketocyclazocine acted at μ-, U-50488 at ϰ-, and dynorphin A1–13 and [d-Ala2,d-Leu5]-enkephalin at δ-receptors. In the mouse vas deferens more excitable fibres are probably equally sensitive to all three types of opioids, whereas less excitable fibres seem to be more sensitive to δ- and ϰ-, than to μ-agonists.

Key words

Opioid receptor types Stimulus intensity Excitatory junction potential Vas deferens 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burnstock G, Bell C (1974) Peripheral autonomic transmission. In: Hubbard JI (ed) The peripheral nervous system. Plenum Press, New York, pp 277–327Google Scholar
  2. Chang K-J, Cooper BR, Hazum E, Cuatrecasas P (1979) Multiple opiate receptors: different regional distribution in the brain and differential binding of opiates and opioid peptides. Mol Pharmacol 16:91–104Google Scholar
  3. Corbett AD, Paterson SJ, McKnight AT, Magnan J, Kosterlitz HW (1982) Dynorphin1–8 and dynorphin1–9 are ligands for the ϰ-subtype of opiate receptor. Nature 299:79–81Google Scholar
  4. Furness JB (1970) The excitatory input to a single smooth muscle cell. Pflügers Arch 314:1–13Google Scholar
  5. Gillan MGC, Kosterlitz HW, Paterson SJ (1980) Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol 70:481–490Google Scholar
  6. Hart SL, Kitchen I, Waddell PR (1979) Different effects of current strength on inhibitory responses of the mouse vas deferens to methionine- and leucine-enkephalin. Br J Pharmacol 66: 361–363Google Scholar
  7. Henderson G, North RA (1976) Depression by morphine of excitatory junction potentials in the vas deferens of the mouse. Br J Pharmacol 57:341–346Google Scholar
  8. Henderson G, Hughes J, Kosterlitz HW (1972) A new example of a morphine-sensitive neuroeffector junction: adrenergic transmission in the mouse vas deferens. Br J Pharmacol 46: 764–766Google Scholar
  9. Holman ME, Taylor GS, Tomita T (1977) Some properties of the smooth muscle of the mouse vas deferens. J Physiol 266: 751–764Google Scholar
  10. Hughes J, Kosterlitz HW, Leslie FM (1975) Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br J Pharmacol 53:371–381Google Scholar
  11. Illes P (1983) Electrophysiology of noradrenaline release from smooth muscle organs. Trends Pharmacol Sci 4:335–338Google Scholar
  12. Illes P, Schulz R (1980) Inhibition of neuroeffector trasmission by morphine in the vas deferens of naive and morphine-treated mice. Br J Pharmacol 71:195–200Google Scholar
  13. Illes P, Zieglgänsberger W, Herz A (1980) Calcium reverses the inhibitory action of morphine on neuroeffector transmission in the mouse vas deferens. Brain Res 191:511–522Google Scholar
  14. James IF, Goldstein A (1984) Site-directed alkylation of multiple opioid receptors. I. Binding selectivity. Mol Pharmacol 25:337–342Google Scholar
  15. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature 267:495–499Google Scholar
  16. Magnan J, Paterson SJ, Tavani A, Kosterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 319:197–205Google Scholar
  17. North RA, Vitek LV (1980) The effect of chronic morphine treatment on excitatory junction potentials in the mouse vas deferens. Br J Pharmacol 68:399–405Google Scholar
  18. Paterson SJ, Robson LE, Kosterlitz HW (1983) Classification of opioid receptors. Br Med Bull 39:31–36Google Scholar
  19. Schulz R, Wüster M, Krenss H, Herz A (1980) Selective development of tolerance without dependence in multiple opiate receptors of mouse vas deferens. Nature 285:242–243Google Scholar
  20. Shaw JS, Miller L, Turnbull MJ, Gormley JJ, Morley JS (1982) Selective antagonists at the opiate delta-receptor. Life Sci 31:1259–1262Google Scholar
  21. Stjärne L, Åstrand P (1984) Discrete events measure single quanta of ATP secreted from sympathetic nerves of guinea-pig and mouse vas deferens. Neuroscience 13:21–28Google Scholar
  22. Stjärne L, Åstrand P (1985) Relative pre- and postjunctional roles of noradrenaline and adenosine 5′-triphosphate as neurotransmitters of the sympathetic nerves of guinea-pig and mouse vas deferens. Neuroscience 14:929–946Google Scholar
  23. Vizi ES (1984) Non-synaptic interactions between neurons: modulation of neurochemical transmission. Pharmacological and clinical aspects. John Wiley and Sons, ChichesterGoogle Scholar
  24. Von Voigtlander PF, Lahti RA, Ludens JH (1983) U-50488: a selective and structurally novel non-mu (kappa) opioid agonist. J Pharmacol Exp Ther 224:7–12Google Scholar
  25. Wallenstein S, Zucker CL, Fleiss JL (1980) Some statistical methods useful in circulation research. Circ Res 47:1–9Google Scholar
  26. Ward SJ, Portoghese PS, Takemori AE (1982) Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation. Eur J Pharmacol 80:377–384Google Scholar
  27. Wüster M, Schulz R, Herz A (1981) Multiple opiate receptors in peripheral tissue preparations. Biochem Pharmacol 30:1883–1887Google Scholar
  28. Yoshimura K, Huidobro-Toro JP, Way EL (1982) Potency of three opiate antagonists to reverse the inhibitory activity of dynorphin, enkephalins and opioid-like alkaloids on the guineapig ileum. Eur J Pharmacol 84:17–24Google Scholar
  29. Zukin RS, Zukin SR (1984) The case for multiple opiate receptors. Trends Neurosci 7:160–164Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • D. Ramme
    • 1
  • P. Illes
    • 1
  1. 1.Department of PharmacologyUniversity of FreiburgFreiburg i. Br.Federal Republic of Germany

Personalised recommendations